HIGHLANDS RANCH, Colo. - Officials from Sandhill Scientific have announced Food and Drug Administration (FDA) approval to market two new modalities for the diagnosis of gastrointestinal disorders.
The MultiChannel Intraluminal Impedance technology was designed to allow characterization of bolus movement within the esophagus. The technology is to be paired with traditional pressure manometry as part of a new device and diagnostic test referred to as esophageal function testing (EFT). It will also be used with a traditional pH ambulatory device that determines reflux episodes.
For additional information, log on to: www.sandhillsci.com.
Long COVID: Urgent Findings, Including Brain Alterations, Call for Renewed Public Health Focus
October 21st 2024New research highlights long COVID’s global impact, cognitive decline, and societal consequences, urging renewed focus on prevention, including vaccination, mask use, and better air quality.